TSC1 and cancer: Given the provided in vitro and in silico data that explore the anti-angiogenic, anti-VEGFR2, and antiproliferative potential in agreement with the initial hypothesis of the TSC1-TSC10 series, we strongly believe that our original work delivered an innovative structural design and SAR observations, which could provide a building block for novel and clinically relevant VEGFR2 inhibitors in the fight against cancer.